We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

PROMEGA

Promega has a portfolio of more than 3,000 products covering the fields of genomics, protein analysis and expression,... read more Featured Products: More products

Download Mobile App




Intestinal Microbiota Determines the Risk of MDRO Acquisition

By LabMedica International staff writers
Posted on 10 Feb 2022

Colonization and infection by multidrug-resistant organisms (MDRO) remains a public health problem. More...

This is particularly important in intensive care units (ICUs) where the risk of MDRO acquisition/colonization results from the selective pressure associated with prolonged broad-spectrum antibiotic treatment.

Control initiatives consist in detecting patients at high risk of MDRO acquisition, implementation of antibiotic stewardship programs, epidemiological surveillance to detect MDRO intestinal carriage, microbiological tests to rapidly identify MDRO and use of effective measures to reduce their nosocomial transmission.

Clinical Microbiologists at the Hospital Clínic de Barcelona (Barcelona, Spain) conducted a prospective study including patients admitted to a 12-bed ICU between July-December 2018. Rectal swabs to detect MDRO intestinal colonization were obtained at ICU admission and weekly thereafter during ICU-stay. Patients were classified into three groups according to MDRO colonization status. Control group included patients who were not colonized by MDROs at ICU admission and did not get colonized during ICU stay.

The team extracted DNA using the PureLink Microbiome DNA Purification kit (Invitrogen, Carlsbad, MA, USA) and quantified using Quantus Flurometer (Promega, Madison, WI, USA). The 16S rRNA gene sequencing was performed on 138 rectal swabs from 62 patients using the sequenced using Illumina MiSeq platform (Illumina, San Diego, CA, USA). After sequence filtering and sample rarefaction alpha and beta diversity indices were obtained using QIIME2 and statistical analyses were performed.

The investigators reported that of the patients studied, 19/62 (30.65%) presented MDRO colonization at admission, 16/62 (25.81%) were colonized during stay and 27/62 (43.55%) were not colonized; 45/62 (72.58%) developed an infection and mortality was 29.03%. Higher bacterial diversity and abundance of Bacillales Family XI incertae sedis and Prevotella families were associated with lower risk of colonization by MDRO, infection and death while Enterococcaceae family was associated with increased risk of infection and death. The lasso regression and the multivariate analysis identified Family XI incertae sedis to be associated with lower risk of infection (OR=0.997) and microbial evenness index to be associated with lower mortality (OR=0.68) risk.

The authors concluded that microbial diversity and abundance of certain bacterial taxa could have prognostic value in patients admitted to a critical care unit. Larger perspective studies should address the value of these markers in clinical practice. The study was published on January 19, 2022 in the journal Clinical Microbiology and Infection.

Related Links:
Hospital Clínic de Barcelona 
Invitrogen 
Promega
Illumina 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Blood proteins measured years before diagnosis may signal future prostate cancer risk, including aggressive disease.(Image Credit: iStock)

Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis

Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.